Navigation Links
Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Date:6/21/2013

SAN DIEGO and IRVINE, Calif., June 21, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq™) and IG-004 (TOCOSOL® paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) in Basel, Switzerland on June 23 - 26. Sorrento has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

IGDRASOL'S data mining of the clinical data for both IG-001 and IG-004 has generated exciting insights into the field of nanomedicine, which will be presented at the joint meeting. These findings are highly relevant to the theme of this year's conference, namely "Nanomedicine & Targeted Medicine – the paradigm of precise, highly effective and innocuous medicine for the benefit of patients and mankind".

IG-001 (Cynviloq™) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM®. It has completed Phase 1 or 2 trials in metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and bladder cancer in the U.S. and/or ex-U.S. IGDRASOL is preparing for an "End of Phase 2" meeting scheduled with the U.S. Food & Drug Administration (FDA) in July 2013, regarding the clinical development of Cynviloq™. As an injectable nanoparticle formulation of paclitaxel, Cynviloq™ may be eligible for approval through the FDA's 505(b)(2) bioequivalence regulatory pathway versus albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) in its currently approved MBC and NSCLC ind
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
2. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
3. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
6. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
7. Sorrento Therapeutics Awarded Third Phase I STTR Grant
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... and ST. LOUIS , May ... pressure or high cholesterol may achieve better health outcomes ... according to early results of a unique program conducted ... ESRX ). "Pharmacists are one of the ... interactions with our members presents enormous opportunities to positively ...
(Date:5/5/2015)... 2015 Big Market Research presents a detailed ... Europe , ( France , Germany ... , UK) and Japan . Current scientific views ... provides the 5-year test volume and sales forecasts by country for ... Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed ...
(Date:5/5/2015)... 2015 E-QURE (Electric Quick Ulcer ... premier provider of innovative medical devices in the field ... to shareholders and the investment community, covering 2014 - ... the proprietary Bioelectrical Signal Therapy™ (BST) Device for advanced ... as well as its plans for commercialization and sale ...
Breaking Medicine Technology:SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 2SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 3SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 42015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 2E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 3E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 4E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 5
(Date:5/5/2015)... May 05, 2015 The global lab ... 2020 from $3,474.2 Million in 2014, at an estimated ... segments the lab automation market on the basis of ... and region. On the basis of application, Lab Automation ... solutions, and proteomics solutions. Drug discovery is a major ...
(Date:5/5/2015)... May 05, 2015 Viverae®, a ... Bard Inc., a leading multinational developer, manufacturer and ... fields of vascular, urology, oncology and surgical specialty ... Award. The Vanguard Award recognizes outstanding achievement ... programs among Viverae’s significant client base. , Viverae ...
(Date:5/5/2015)... Dr. Patricia George knows all too well the ... pulmonary hypertension specialist at the University of Pittsburgh Medical ... an initial idea entered her mind for Team PHenomenal ... at the 2010 PHA International Conference,” George recalled. “The ... recalling their climb up Mt. Kilimanjaro and I remember ...
(Date:5/5/2015)... In a April 25, 2015, report published in ... Missouri State Highway Patrol (MSHP) announced that Indiana led the ... the second year in a row. , The MSHP, ... incidents in 2014 alone, around 15% of the national total. ... US Population calls Indiana home, according to the report. , ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 ... Platform that enables businesses to deploy Mobile Engagement Campaigns ... Constant Contact . ProTexting clients can now leverage the ... reach by collecting and syncing subscribers’ e-mail addresses into ... says “We have recognized that the growing trend of ...
Breaking Medicine News(10 mins):Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:World PH Day: Team PHenomenal Hope Races to Spread the Word about Pulmonary Hypertension 2Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3
... occurs in sperm could be the key to a new ... an ion channel protein that controls the flow of calcium ... swim, so a drug designed to block the channel would ... in this week's Nature by Dr Arnold Clapham, from the ...
... cell disease is an inherited blood disorder that affects ... red blood cells that contain an abnormal type of ... have difficulty passing through small blood vessels. When sickle-shaped ... is often pain severe enough to require hospital admission. ...
... intestine could hold the key to permanent weight loss. ... is produced in the small intestine in response to ... development of better treatments for eating disorders and obesity. ... and profoundly different from those of traditional appetite suppressants. ...
... that tend to be slightly elevated but still considered ... for suffering from heart disease. Blood pressure readings are ... first number in a blood pressure measurement, represents the ... the diastolic value, represents the pressure when the heart ...
... be mindful of the possible interaction between oral ... Centers for Disease Control and Prevention (CDC) to ... and anti-infective medications, such as Cipro, doxycycline, and ... have been exposed to anthrax spores.// Many antibiotics ...
... significant breakthrough, a team of scientists have successfully transplanted ... diseased one, bringing light to the people who nearly ... about stem cells, in all 33 patients who suffered ... drug and auto-immune diseases causing damage to the part ...
Cached Medicine News:
For the quantitative determination of total protein in serum. Linearity: 1-15 g/dl....
... the quantitative determination of urea ... lag phase of less than ... phase of at least 240 ... 100 mg/dL (35.6 mmol/L urea) ...
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
Medicine Products: